5 completed. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 2 |
Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer Prolgolimab - Colorectal Cancer | Phase 2 | Completed | Blokhin's Russian Cancer Research Center | 30 | 2022-03-31 | 2026-04-27 |
| Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status temozolomide (induction),, pembrolizumab (treatment) - Colorectal Neoplasms, Microsatellite Instability | Phase 2 | Completed | IFOM ETS - The AIRC Institute of Molecular Oncology | 107 | 2019-01-23 | 2026-03-03 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Nivolumab - Carcinoma, Renal Cell, Head and Neck Neoplasm | Phase 2 | Completed | UNICANCER | 269 | 2017-06-16 | 2024-02-28 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 444 | 2014-07-17 | 2022-02-14 |
Colorectal Neoplasms (3) · Carcinoma, Renal Cell (2) · Head and Neck Neoplasms (2) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Penile Neoplasms (1) · Rectal Neoplasms (1) · Skin Neoplasms (1)
Genomic Instability (5) · Neoplasms (5) · Neoplasms by Site (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Colonic Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Adenocarcinoma (2) · Carcinoma (2)
pembrolizumab (2) · Neoadjuvant Therapy (1) · Nivolumab (1) · Temozolomide (1) · Therapeutics (1) · bintrafusp alfa protein, human (1) · epacadostat (1)
Blokhin's Russian Cancer Research Center (1) · IFOM ETS - The AIRC Institute of Molecular Oncology (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · UNICANCER (1)
United States (2) · France (1) · Italy (1) · Russia (1)
Mark Jones, MD (1) · Salvatore Siena, MD (1) · Silvia Marsoni, MD (1) · Van K Morris, MD (1)
PMID 33109741, PMID 35522273, PMID 35791694, PMID 39594133, PMID 41370727
2016 (1), 2018 (1)